Literature DB >> 10749558

Cathepsin A activity in primary and metastatic human melanocytic tumors.

L Kozlowski1, M Z Wojtukiewicz, H Ostrowska.   

Abstract

Several lysosomal proteases including cathepsins B, D, H and L have been found to play a role in the metastasis of tumor cells. However, up to now no information on the role of cathepsin A, a lysosomal multifunctional peptidase, in the proliferative, invasive, and metastatic potential of malignant tumors has been available. In the present study we compared the activity of cathepsin A in lysates of 34 human melanocytic tumors: primary (n = 12) and metastatic (n = 5) malignant melanoma, dysplastic pigmented nevi (n = 6) and pigmented nevi without evidence of dysplastic melanocytes (n = 11). The carboxypeptidase activity of cathepsin A was assayed at pH 5.0 with its specific substrate Cbz-Phe-Ala. The amount of released C-terminal alanine was measured by the ninhydrin method. We found that lysates of primary malignant melanoma lesions exhibited significantly higher cathepsin A activity than lysates of dysplastic and normal pigmented nevi. The cathepsin A activity in lysates of metastatic lesions of malignant melanoma was significantly higher than in primary focus lysates. It seems that cathepsin A may play a role in malignant transformation and metastatic dissemination of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10749558     DOI: 10.1007/s004030050012

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  13 in total

Review 1.  Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

Authors:  Eleonore Fröhlich
Journal:  Cell Mol Life Sci       Date:  2010-08-05       Impact factor: 9.261

2.  'Patchiness' and basic cancer research: unravelling the proteases.

Authors:  Surinder M Soond; Maria V Kozhevnikova; Andrey A Zamyatnin
Journal:  Cell Cycle       Date:  2019-06-24       Impact factor: 4.534

3.  High cathepsin A protein expression predicts poor prognosis and tumor recurrence of hepatocellular carcinoma patients after curative hepatectomy.

Authors:  Laibang Luo; Xuyang Wang; Huaxiang Wang; Chengkai Yang; Youfu Zhang; Xinchang Li; Zhidan Xu
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

Review 4.  Cathepsins mediate tumor metastasis.

Authors:  Gong-Jun Tan; Zheng-Ke Peng; Jin-Ping Lu; Fa-Qing Tang
Journal:  World J Biol Chem       Date:  2013-11-26

Review 5.  Role of lysosomes in physiological activities, diseases, and therapy.

Authors:  Ziqi Zhang; Pengfei Yue; Tianqi Lu; Yang Wang; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2021-05-14       Impact factor: 17.388

6.  Transcriptional network analysis reveals that AT1 and AT2 angiotensin II receptors are both involved in the regulation of genes essential for glioma progression.

Authors:  Hátylas Azevedo; André Fujita; Silvia Yumi Bando; Priscila Iamashita; Carlos Alberto Moreira-Filho
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

7.  Quantitative Proteomic Profiling of Tachyplesin I Targets in U251 Gliomaspheres.

Authors:  Xuan Li; Jianguo Dai; Yongjun Tang; Lulu Li; Gang Jin
Journal:  Mar Drugs       Date:  2017-01-18       Impact factor: 5.118

8.  Increased phosphorylation of eIF2α in chronic myeloid leukemia cells stimulates secretion of matrix modifying enzymes.

Authors:  Paulina Podszywalow-Bartnicka; Anna Cmoch; Magdalena Wolczyk; Lukasz Bugajski; Marta Tkaczyk; Michal Dadlez; Margaret Nieborowska-Skorska; Antonis E Koromilas; Tomasz Skorski; Katarzyna Piwocka
Journal:  Oncotarget       Date:  2016-11-29

9.  Prognostic significance and oncogene function of cathepsin A in hepatocellular carcinoma.

Authors:  Huaxiang Wang; Fengfeng Xu; Fang Yang; Lizhi Lv; Yi Jiang
Journal:  Sci Rep       Date:  2021-07-16       Impact factor: 4.379

10.  Cathepsin K associates with lymph node metastasis and poor prognosis in oral squamous cell carcinoma.

Authors:  Frank K Leusink; Eleftherios Koudounarakis; Michael H Frank; Ronald Koole; Paul J van Diest; Stefan M Willems
Journal:  BMC Cancer       Date:  2018-04-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.